Skip to content
Bored Studies
RecruitingPhase 3

Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for Suspected Right-to-left Shunt

Agitated Solutions, Inc. · with Bright Research Partners · NCT06938347

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
300
US sites recruiting
7
Study start
November 5, 2025
Record last updated
July 6, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This is a phase 3, multicenter, open-label, blinded, crossover trial in which each participant will undergo a randomized sequence of ASI-02 and agitated saline standard of care (SoC) via a saline contrast transthoracic echocardiogram (TTE) study.

Being studied: Agitated Saline SoC; ASI-02

Conditions: Right-To-Left Shunt

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Patient is clinically indicated for a saline contrast TTE study with a suspected right-to-left shunt
  • Patient must be at least 18 years of age inclusive, at the time of signing the informed consent
  • Able to communicate effectively with trial personnel

Exclusion Criteria

  • Female patients who are pregnant or lactating. All women of child-bearing potential (WOCBP) must have a negative urine pregnancy test at screening regardless of contraceptive use history
  • WOCBP are excluded unless they have been using an adequate and medically approved method of contraception to avoid pregnancy for at least 1 month prior to ASI-02 dose administration
  • Allergy to polysorbate 80 (PS-80)
  • American Society of Anesthesiologists (ASA) physical status classification IV, V, or VI, except that participants with ASA physical status IV due solely to recent suspected transient ischemic attack or cerebrovascular accident are eligible for inclusion
  • Current illness or pathology that in the opinion of the investigator would prevent undergoing investigational product administration due to a significant safety risk to the patient
  • Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic blood pressure ≤ 90 mmHg)
  • Unstable cardiovascular status defined as:
  • myocardial infarction or unstable angina pectoris within 6 months prior to procedure day
  • symptomatic valvular heart disease or moderate to severe stenotic valvular heart disease
  • clinically significant congenital heart defects (excluding an atrial septal defect [ASD], patent foramen ovale [PFO], or pulmonary arteriovenous malformation [PAVM])
  • current uncontrolled cardiac arrhythmias causing clinical symptoms requiring medical intervention or hemodynamic compromise
  • acute pulmonary embolus or pulmonary infarction
  • acute myocarditis or pericarditis
  • acute aortic dissection
  • untreated atrial fibrillation
  • Any major surgery within 30 days prior to screening
  • Participation in any investigational drug, device, or placebo study within 30 days prior to screening
  • Vulnerable adult participant populations (e.g., incarcerated or cognitively challenged adults)

Recruiting US locations

  • Northwestern University

    Chicago, IL 60611

    Site contact: Akhil Narang, MD

  • AH Illinois Masonic Center

    Chicago, IL 60657

    Site contact: Sorin Danciu, MD

  • Mayo Clinic

    Rochester, MN 55905

    Site contact: Sunil Mankad, MD

  • CentraCare

    Saint Cloud, MN 56303

    Site contact: Timothy Schuchard, MD

  • Jackson Heart Clinic

    Jackson, MS 39216

    Site contact: William Crowder, MD

  • NYU Langone Health

    New York, NY 10016

    Site contact: Daniel Bamira, MD

  • Aurora St. Lukes Medical Center

    Milwaukee, WI 53215

    Site contact: Renuka Jain, MD

Study contacts (from the official record)

  • Pamela Wolfe · 763-258-7027 · pamela@agitatedsolutions.com
  • Rebecca Zickert · 612-345-4544 · rebecca.zickert@brightresearch.com
Comparing the Safety and Efficacy of ASI-02 to Agitated Saline for… (NCT06938347) | Bored Studies